A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Kidney Failure, Chronic Clinical Trial

Official title:

A Two-Part Phase 2a Study in Patients With End-Stage Renal Disease Treated With Hemodialysis; Part A is an Open-Label Study Arm to Evaluate the Effect of Hemodialysis on the Pharmacokinetics of 100 mg RVX000222; and Part B is a Double-Blind, Randomized, Placebo-Controlled, Sequential Cross-Over Study Arm to Evaluate the Efficacy, Safety, and Pharmacokinetics of RVX000222

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03160430
• Other study ID #: RVX222-CS-018
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: November 22, 2024
• Est. completion date: November 22, 2026

Study information

• Verified date: November 2023
• Source: Resverlogix Corp
• Contact: Sr. Director of Clinical Operations
• Phone: 403-254-9252
• Email: clinicaltrials[@]resverlogix.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, two-part study; Part A and Part B. Part A of the study is an open-label, single-dose pharmacokinetic (PK) evaluation of 100 mg RVX000222 on dialysis and non-dialysis days in eight (8) End Stage Renal Disease (ESRD) patients who receive hemodialysis as standard of care.

Part B of the study is a double-blind, placebo-controlled study in up to thirty six (36) ESRD patients receiving hemodialysis using a sequential cross-over design with RVX000222 at a daily oral dose of 100 mg b.i.d. (200 mg per day) or matching placebo in combination with SoC.

The primary objective of the study is to evaluate if treatment with RVX000222 in combination with standard of care (SoC) decreases plasma alkaline phosphatase in comparison to placebo and SoC.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 44
• Est. completion date: November 22, 2026
• Est. primary completion date: November 22, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Men or women =18 and =80 years of age.

2. Diagnosis of end-stage renal disease and receiving hemodialysis an average of three (3) times per week for at least ninety (90) days prior to Enrollment/Visit 2.

3. Clinically stable, in the judgment of the investigator.

4. Female subjects must meet one of the following:

1. If of childbearing potential, must have a negative serum pregnancy test and be willing and able to use medically acceptable non-hormonal method of birth control (non-hormonal intrauterine device, condom, or diaphragm) or remain abstinent from Screen until Follow-up Visit, or

2. Be of non-child-bearing potential: post-surgical sterilization (hysterectomy or a bilateral oophorectomy) or post-menopausal. Post-menopausal is defined as amenorrhea for =2 years at Screen/Visit 1.

5. In the view of the investigator, during the course of the trial, subject is expected to:

1. remain on unchanged standard of care medication from 4 weeks prior to Enrollment/Visit 2.

2. not require hospitalization for any condition other than routine hemodialysis.

6. Have given signed informed consent to participate in the study.

Exclusion Criteria:

1. Planned major surgery in the next 4 months, including renal transplant, from Enrollment/Visit 2.

2. Major surgery, in the judgement of the investigator, within 12 weeks before enrollment/Visit 2 (excluding vascular access surgery).

3. Hospitalization for congestive heart failure, myocardial infarction, deep vein thrombosis, stroke or transient ischemic attack or peripheral arterial disease within 6 months before Enrollment/Visit 2.

4. New York Heart Association (NYHA) Classification, Class III or IV Heart Failure at Screen/Visit 1.

5. Diastolic blood pressure >110 mm Hg or systolic blood pressure >180 mm Hg during screen.

6. Currently receiving antibiotic therapy for systemic infection.

7. In the judgement of the Investigator, evidence of active hepatitis. Hepatitis serology testing will be performed at Screen/Visit 1.

8. History of malignancy of any organ system, treated or untreated, within the past 2 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.

9. Red blood cell (RBC) transfusions within 12 weeks before Enrollment/Visit 2.

10. Current or recent (within 12 months prior to Visit 1) treatment with immunosuppressants (e.g., cyclosporine).

11. Use of fibrates at any dose or niacin/nicotinic acid 250 mg or more within 30 days prior to Screen/Visit 1.

12. Diagnosis of systemic hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, hematologic malignancy, myeloma, hemolytic anemia).

13. Hemoglobin <9.5 g/dL at Screen/Visit 1.

14. Alanine aminotransferase (ALT) >1.5 x upper limit of normal (ULN) at Screen/Visit 1.

15. Bilirubin >1.0 x ULN at Screen/Visit 1.

16. Pregnant or breast-feeding women.

17. Any condition which, in the opinion of the investigator, may place the subject at higher risk from his/her participation in the study, or is likely to prevent the subject from complying with the requirements of the study or completing the study.

18. Treatment with an investigational agent or device within 30 days or 5 half-lives before Enrollment/Visit 2 or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study.

19. History of noncompliance with medical regimens or unwillingness to comply with the study protocol.

20. In the judgement of the Investigator, any disorder that may impact the ability to give informed consent for participation in this study.

21. Any condition that, in the opinion of the investigator, would confound the evaluation and interpretation of efficacy and/or safety data.

22. Persons directly involved in the execution of this protocol.

Exclusion Criteria, Part A Only:

23. Are unwilling to abstain from alcoholic beverages, caffeine or xanthine-containing products (e.g., tea, coffee, chocolate, cola), and use of nicotine products from 24 hours prior to Clinical Research Unit (CRU) admission to 48 hours post RVX000222 dose administration.

Exclusion Criteria, Part B Only:

23. Parathyroid hormone, intact (PTH, intact) <150 pg/mL or >800 pg/mL at Screen/Visit 1.

Related Conditions & MeSH terms

• Kidney Diseases
• Kidney Failure, Chronic
• Renal Insufficiency

Intervention

Drug:
• apabetalone
RVX000222 oral (apabetalone), 100 mg capsule
• Placebos
matching placebo capsule

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Resverlogix Corp

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent change in alkaline phosphatase (ALP) concentration (Part B)	The primary endpoint of the study is the comparison of the RVX000222 treatment period to the placebo period in the percent change in ALP concentration. Percent change is computed relative to the beginning of each period.	Percent change is computed relative to the beginning of each period (6 weeks)
Primary	Single Dose Cmax of RVX000222 (apabetalone) and the Metabolites RVX000288 and RVX000404	Primary PK comparison between dialysis (test) and non-dialysis (reference) days for Cmax of RVX000222 and its two principal metabolites, RVX000288 and RVX000404	48 hours
Primary	Single Dose AUC of RVX000222 (apabetalone) and the Metabolites RVX000288 and RVX000404	Primary PK comparison between dialysis (test) and non-dialysis (reference) days for AUC of RVX000222 and its two principal metabolites, RVX000288 and RVX000404	48 hours
Secondary	Changes in high-sensitivity C-Reactive Protein (hsCRP)	Changes in hsCRP in dialysis patients at the end of the RVX000222 treatment period relative to the end of the placebo period	6 weeks
Secondary	Changes in Interleukin-13 (IL-13)	Changes in IL-13 in dialysis patients at the end of the RVX000222 treatment period relative to the end of the placebo period	6 weeks
Secondary	Changes in Interleukin-6 (IL-6)	Changes in IL-6 in dialysis patients at the end of the RVX000222 treatment period relative to the end of the placebo period	6 weeks
Secondary	Changes in Interleukin-8 (IL-8)	Changes in IL-8 in dialysis patients at the end of the RVX000222 treatment period relative to the end of the placebo period	6 weeks
Secondary	Changes in Monocyte Chemoattractant Protein-1 (MCP-1)	Changes in MCP-1 in dialysis patients at the end of the RVX000222 treatment period relative to the end of the placebo period	6 weeks
Secondary	Change in key markers of vascular mineralization	Change in key markers of vascular mineralization i.e. RANKL and osteoprotegerin at the end of the RVX000222 treatment period relative to the end of the placebo period	6 weeks
Secondary	Changes in ALP isoenzymes	Changes in ALP isoenzymes at the end of the RVX000222 treatment period relative to the end of the placebo period	6 weeks
Secondary	Changes in Parathyroid hormone (PTH)	Changes in parathyroid hormone at the end of the RVX000222 treatment period relative to the end of the placebo period	6 weeks
Secondary	Change in apolipoprotein A1 (apoA-I), HDL-C, LDL-C, apolipoprotein B (apoB), and triglycerides	Change in apoA-I, HDL-C, LDL-C, apoB, and triglycerides at the end of the RVX000222 treatment period relative to the end of the placebo period	6 weeks
Secondary	Change in Analyzing Data, Recognizing Excellence and Optimizing Outcomes All-Cause Mortality Risk Score For Patients on Chronic Hemodialysis (ARO Score)	Change in ARO Score at the end of the RVX000222 treatment period relative to the end of the placebo period	6 weeks